Indication

HER2-mutant non-small cell lung cancer

HER2-mutant non-small cell lung cancer is a distinct molecular subtype of non-small cell lung cancer characterized by activating somatic mutations in the *ERBB2* (HER2) gene. Read more about HER2-mutant non-small cell lung cancer

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common HER2-mutant non-small cell lung cancer therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with HER2-mutant non-small cell lung cancer preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About HER2-mutant non-small cell lung cancer.

HER2-mutant non-small cell lung cancer is a distinct molecular subtype of non-small cell lung cancer characterized by activating somatic mutations in the *ERBB2* (HER2) gene.

Primarily arising in lung adenocarcinomas, this malignancy disproportionately affects non-smokers and female patients, representing roughly two to four percent of all non-small cell lung cancer cases.

Pathophysiologically, these genetic alterations—most frequently in-frame insertions within exon 20 of the kinase domain—lead to constitutive, ligand-independent activation of HER2 receptor tyrosine kinase signaling, driving downstream oncogenic pathways that promote uncontrolled cellular proliferation, survival, and disease progression.

Personalize your experience

Follow HER2-mutant non-small cell lung cancer and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it